PTX - Pernix Therapeutics: It Seems A Serious Sell
Pernix Therapeutics (PTX) has its book value per share of -$14, and the revenues declined in the nine months ended September 30, 2018. In addition, the company reports a large amount of financial debt, which should be paid in August 2020. Pernix Therapeutics does not seem to have sufficient cash to pay. As a result, the share price is expected to decline until August 2020. Keep in mind that the company may try to convert debt into equity or sell equity. Such type of transactions should reduce the value of the shares.